Cargando…
Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis – cross-sectional study and literature review
Abstract Rationale: Anti-CCP antibodies are detectable not only in rheumatoid arthritis (RA), but also in psoriatic arthritis (PsA). It is possible those anti-CCP antibodies are associated with features of PsA and that these auto-antibodies are useful in distinguishing PsA from RA. Objective: to eva...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973875/ https://www.ncbi.nlm.nih.gov/pubmed/24701255 |
_version_ | 1782479385244205056 |
---|---|
author | Popescu, C Zofotă, S Bojincă, V Ionescu, R |
author_facet | Popescu, C Zofotă, S Bojincă, V Ionescu, R |
author_sort | Popescu, C |
collection | PubMed |
description | Abstract Rationale: Anti-CCP antibodies are detectable not only in rheumatoid arthritis (RA), but also in psoriatic arthritis (PsA). It is possible those anti-CCP antibodies are associated with features of PsA and that these auto-antibodies are useful in distinguishing PsA from RA. Objective: to evaluate the prevalence and the associations of anti-CCP antibodies in PsA patients; to evaluate the usefulness of anti-CCP antibodies in distinguishing PsA from RA. Methods and Results: The inquiry was designed as a cross-sectional study of 41 PsA patients, 139 RA patients and 147 normal subjects, which recorded demographic data, disease activity and serology: rheumatoid factor (RF), anti-CCP antibodies. Five PsA patients (12.2%) were anti-CCP positive. Compared to anti-CCP negative PsA patients, anti-CCP positive PsA patients had a more frequently a polyarticular disease pattern (p = 0.005), they were more frequently treated with biologics (p = 0.015) and less frequently with classic disease-modifying drugs (p < 0.001). An optimal positive cutoff value for anti-CCP titer was determined (11.6 U/mL), over which it is highly probable that a known PsA patient actually has RA and psoriasis. Discussion: The more aggressive the disease of anti-CCP positive PsA patients indicates the need of a more intensive management regarding anti-rheumatic treatment and follow-up. Anti-CCP antibodies can be a useful tool in differentiating PsA from RA, especially in RA-like forms of PsA, which present no elements pertaining to spondyloarthropathies. Abbreviations: anti-CCP - anti-cyclic citrullinated peptide antibodies; ACR - America College of Rheumatology; CRP - C-reactive protein; CASPAR - The Classification Criteria for Psoriatic Arthritis; DMARD – disease modifying anti-rheumatic drug; EULAR - European League against Rheumatism; ELISA - enzyme-linked immunosorbent assay; ESR - erythrocyte sedimentation rate; HLA – human leukocyte antigen; PsA - psoriatic arthritis; RA - rheumatoid arthritis; RF - rheumatoid factor; ROC - receiver operating characteristic. |
format | Online Article Text |
id | pubmed-3973875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Carol Davila University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-39738752014-04-03 Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis – cross-sectional study and literature review Popescu, C Zofotă, S Bojincă, V Ionescu, R J Med Life Review Abstract Rationale: Anti-CCP antibodies are detectable not only in rheumatoid arthritis (RA), but also in psoriatic arthritis (PsA). It is possible those anti-CCP antibodies are associated with features of PsA and that these auto-antibodies are useful in distinguishing PsA from RA. Objective: to evaluate the prevalence and the associations of anti-CCP antibodies in PsA patients; to evaluate the usefulness of anti-CCP antibodies in distinguishing PsA from RA. Methods and Results: The inquiry was designed as a cross-sectional study of 41 PsA patients, 139 RA patients and 147 normal subjects, which recorded demographic data, disease activity and serology: rheumatoid factor (RF), anti-CCP antibodies. Five PsA patients (12.2%) were anti-CCP positive. Compared to anti-CCP negative PsA patients, anti-CCP positive PsA patients had a more frequently a polyarticular disease pattern (p = 0.005), they were more frequently treated with biologics (p = 0.015) and less frequently with classic disease-modifying drugs (p < 0.001). An optimal positive cutoff value for anti-CCP titer was determined (11.6 U/mL), over which it is highly probable that a known PsA patient actually has RA and psoriasis. Discussion: The more aggressive the disease of anti-CCP positive PsA patients indicates the need of a more intensive management regarding anti-rheumatic treatment and follow-up. Anti-CCP antibodies can be a useful tool in differentiating PsA from RA, especially in RA-like forms of PsA, which present no elements pertaining to spondyloarthropathies. Abbreviations: anti-CCP - anti-cyclic citrullinated peptide antibodies; ACR - America College of Rheumatology; CRP - C-reactive protein; CASPAR - The Classification Criteria for Psoriatic Arthritis; DMARD – disease modifying anti-rheumatic drug; EULAR - European League against Rheumatism; ELISA - enzyme-linked immunosorbent assay; ESR - erythrocyte sedimentation rate; HLA – human leukocyte antigen; PsA - psoriatic arthritis; RA - rheumatoid arthritis; RF - rheumatoid factor; ROC - receiver operating characteristic. Carol Davila University Press 2013-12-15 2013-12-25 /pmc/articles/PMC3973875/ /pubmed/24701255 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Popescu, C Zofotă, S Bojincă, V Ionescu, R Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis – cross-sectional study and literature review |
title | Anti-cyclic citrullinated peptide antibodies in psoriatic
arthritis – cross-sectional study and literature review |
title_full | Anti-cyclic citrullinated peptide antibodies in psoriatic
arthritis – cross-sectional study and literature review |
title_fullStr | Anti-cyclic citrullinated peptide antibodies in psoriatic
arthritis – cross-sectional study and literature review |
title_full_unstemmed | Anti-cyclic citrullinated peptide antibodies in psoriatic
arthritis – cross-sectional study and literature review |
title_short | Anti-cyclic citrullinated peptide antibodies in psoriatic
arthritis – cross-sectional study and literature review |
title_sort | anti-cyclic citrullinated peptide antibodies in psoriatic
arthritis – cross-sectional study and literature review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973875/ https://www.ncbi.nlm.nih.gov/pubmed/24701255 |
work_keys_str_mv | AT popescuc anticycliccitrullinatedpeptideantibodiesinpsoriaticarthritiscrosssectionalstudyandliteraturereview AT zofotas anticycliccitrullinatedpeptideantibodiesinpsoriaticarthritiscrosssectionalstudyandliteraturereview AT bojincav anticycliccitrullinatedpeptideantibodiesinpsoriaticarthritiscrosssectionalstudyandliteraturereview AT ionescur anticycliccitrullinatedpeptideantibodiesinpsoriaticarthritiscrosssectionalstudyandliteraturereview |